Head and neck cancer: From research to therapy and cure

Annals of the New York Academy of Sciences

Volumn 1333, Issue 1, 2014, Pages 1-32

  Varelas, Xaralabos ^a   Kukuruzinska, Maria A ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

Genomics; Head and neck cancer; HPV; NOTCH; Pathway networks; PI3K; Precision medicine; Robotic surgery; STAT

Indexed keywords

HUMAN PAPILLOMAVIRUS;

TUMOR MARKER;

ANIMAL; HEAD AND NECK NEOPLASMS; HUMAN; METABOLISM; PAPILLOMAVIRUS INFECTIONS; PERSONALIZED MEDICINE;

ANIMALS; HEAD AND NECK NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; PAPILLOMAVIRUS INFECTIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 84919639750     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12613     Document Type: Article

References (73)

1. Kern, S.E., E.R. Fearon, K.W. Tersmette, et al. 1989. Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. JAMA 261: 3099-3103.
2. Hanahan, D. & R.A. Weinberg . 2011. Hallmarks of cancer: the next generation. Cell 144: 646-674.
3. Scheel, C. & R.A. Weinberg . 2011. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer and normal stem cells? Int. J. Cancer 129: 2310-2314.
4. Kalluri, R. & R.A. Weinberg . 2009. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119: 1420-1428.
5. Chaffer, C.L., I. Brueckmann, C. Scheel, et al. 2011. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl. Acad. Sci. USA 108: 7950-7955.
6. Gupta, P.B., T.T. Onder, G. Jiang, et al. 2009. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659.
7. Hartl, D.M., D.F. Brasnu, J.P. Shah, et al. 2013. Is open surgery for head and neck cancers truly declining? Eur. Arch. Oto-rhino-laryngol. 270: 2793-2802.
8. Ho, A.S., D.H. Kraus, I. Ganly, et al. 2014. Decision making in the management of recurrent head and neck cancer. Head Neck 36: 144-151.
9. Ganly, I., D. Goldstein, D.L. Carlson, et al. 2013. Long-term regional control and survival in patients with "low-risk, " early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation: the importance of tumor thickness. Cancer 119: 1168-1176.
10. Francis, E., N. Matar, N. Khoueir, et al. 2014. T4a laryngeal cancer survival: retrospective institutional analysis and systematic review. Laryngoscope 124: 1618-1623.
11. Nankivell, P., H. Williams, P. Matthews, et al. 2013. The binary oral dysplasia grading system: validity testing and suggested improvement. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 115: 87-94.
12. Zeng, Q., S. Chen, Z. You, et al. 2002. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFκB. J. Biol. Chem. 277: 25203-25208.
13. Zeng, Q., S. Li, D.B. Chepeha, et al. 2005. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8: 13-23.
14. Shaulian, E. & M. Karin . 2002. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4: E131-E136.
15. Ding, X., H. Pan, J. Li, et al. 2013. Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis. Sci. Signal 6: ra28 21-13, S20-15.
16. Vogelstein, B., N. Papadopoulos, V.E. Velculescu, et al. 2013. Cancer genome landscapes. Science 339: 1546-1558.
17. Agrawal, N., M.J. Frederick, C.R. Pickering, et al. 2011. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157.
18. Stransky, N., A.M. Egloff, A.D. Tward, et al. 2011. The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160.
19. Lui, V.W., M.L. Hedberg, H. Li, et al. 2013. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 3: 761-769.
20. Brakenhoff, R.H. 2011. Cancer: another NOTCH for cancer. Science 333: 1102-1103.
21. Chiosea, S.I., J.R. Grandis, V.W. Lui, et al. 2013. PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. BMC Cancer 13: 602.
22. - tumors. Genome Med. 5: 49.
23. Lui, V.W., N.D. Peyser, P.K. Ng, et al. 2014. Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. Proc. Natl. Acad. Sci. USA 111: 1114-1119.
24. Sen, M., S.M. Thomas, S. Kim, et al. 2012. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2: 694-705.
25. Seiwert, T.Y., Z. Zuo, M.K. Keck, et al. 2014. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin. Cancer Res.
26. Liao, R.G., J. Jung, J. Tchaicha, et al. 2013. Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma. Cancer Res. 73: 5195-5205.
27. Dutt, A., A.H. Ramos, P.S. Hammerman, et al. 2011. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 6: e20351.
28. Wu, Y.M., F. Su, S. Kalyana-Sundaram, et al. 2013. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 3: 636-647.
29. Lynch, T.J., D.W. Bell, R. Sordella, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350: 2129-2139.
30. Weinstein, I.B. 2002. Cancer: addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
31. Corcoran, R.B., S.M. Rothenberg, A.N. Hata, et al. 2013. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci. Transl. Med. 5: 196ra198.
32. Rothenberg, S.M. & L.W. Ellisen . 2012. The molecular pathogenesis of head and neck squamous cell carcinoma. J. Clin. Invest. 122: 1951-1957.
33. Yang, W., J. Soares, P. Greninger, et al. 2013. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41: D955-961.
34. Rothenberg, S.M., G. Mohapatra, M.N. Rivera, et al. 2010. A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 70: 2158-2164.
35. D'Souza, G., A.R. Kreimer, R. Viscidi, et al. 2007. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356: 1944-1956.
36. Gillison, M.L., G. D'Souza, W. Westra, et al. 2008. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl. Cancer Inst. 100: 407-420.
37. Peters, L.J., B. O'Sullivan, J. Giralt, et al. 2010. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J. Clin. Oncol. 28: 2996-3001.
38. Ang, K.K., J. Harris, R. Wheeler, et al. 2010. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363: 24-35.
39. Fakhry, C., W.H. Westra, S. Li, et al. 2008. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 100: 261-269.
40. Mesri, E.A., M.A. Feitelson, & K. Munger . 2014. Human viral oncogenesis: a cancer hallmarks analysis. Cell Host Microbe 15: 266-282.
41. McLaughlin-Drubin, M.E., C.P. Crum & K. Munger . 2011. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc. Natl. Acad. Sci. USA 108: 2130-2135.
42. Applebaum, K.M., C.S. Furniss & A. Zeka . 2007. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. J. Natl. Cancer Inst. 99: 1801-1810.
43. Liang, C., C.J. Marsit & M.D. McClean . 2012. Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res. 72: 5004-5013.
44. Shiboski, C.H., B.L. Schmidt & R.C. Jordan . 2005. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 103: 1843-1849.
45. Tsunokawa, Y., N. Takebe, S. Nozawa, et al. 1986. Presence of human papillomavirus type-16 and type-18 DNA sequences and their expression in cervical cancers and cell lines from Japanese patients. Int. J. Cancer 37: 499-503.
46. Walboomers, J.M., M.V. Jacobs, M.M. Manos, et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189: 12-19.
47. Capone, R.B., S.I. Pai, W.M. Koch, et al. 2000. Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin. Cancer Res. 6: 4171-4175.
48. Gillison, M.L., W.M. Koch, R.B. Capone, et al. 2000. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 92: 709-720.
49. Daniels, T.E., D. Cox, C.H. Shiboski, et al. 2011. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjogren's syndrome among 1726 registry participants. Arthritis Rheum. 63: 2021-2030.
50. Maxwell, J.H., B. Kumar, F.Y. Feng, et al. 2010. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin. Cancer Res. 16: 1226-1235.
51. Worden, F.P., B. Kumar, J.S. Lee, et al. 2008. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J. Clin. Oncol. 26: 3138-3146.
52. Stenmark, M.H., J.B. McHugh, M. Schipper, et al. 2014. Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis. Int. J. Radiat. Oncol. Biol. Phys. 88: 580-588.
53. Slaughter, D.P., H.W. Southwick & W. Smejkal . 1953. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6: 963-968.
54. Dotto, G.P. 2014. Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. J. Clin. Invest. 124: 1446-1453.
55. Dotto, G.P. 2009. Crosstalk of Notch with p53 and p63 in cancer growth control. Nat. Rev. Cancer 9: 587-595.
56. Hu, B., E. Castillo, L. Harewood, et al. 2012. Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling. Cell 149: 1207-1220.
57. Kuilman, T. & D.S. Peeper . 2009. Senescence-messaging secretome: SMS-ing cellular stress. Nat. Rev. Cancer 9: 81-94.
58. Goruppi, S. & G.P. Dotto . 2013. Mesenchymal stroma: primary determinant and therapeutic target for epithelial cancer. Trends Cell Biol. 23: 593-602.
59. Brooks, Y.S., P. Ostano, S.H. Jo, et al. 2014. Multifactorial ERbeta and NOTCH1 control of squamous differentiation and cancer. J. Clin. Invest. 124: 2260-2276.
60. de Castro, G., Jr. & M.V. Negrao . 2014. The Cancer Genome Atlas findings in head and neck cancer: a renewed hope. Curr. Opin. Oncol. 26: 245-246.
61. Parfenov, M., C.S. Pedamallu, N. Gehlenborg, et al. 2014. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc. Natl. Acad. Sci. USA 111: 15544-15549.
62. Zhang, Q.S., L. Eaton, E.R. Snyder, et al. 2008. Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice. Cancer Res. 68: 1601-1608.
63. Vermorken, J.B. & P. Specenier . 2010. Optimal treatment for recurrent/metastatic head and neck cancer. Ann. Oncol. 21(Suppl. 7): vii252-vii261.
64. Vermorken, J.B., R. Mesia, F. Rivera, et al. 2008. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359: 1116-1127.
65. Vermorken, J.B., J. Trigo, R. Hitt, et al. 2007. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 25: 2171-2177.
66. Vermorken, J.B., J. Stohlmacher-Williams, I. Davidenko, et al. 2013. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 14: 697-710.
67. Machiels, J.P., S. Subramanian, A. Ruzsa, et al. 2011. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 12: 333-343.
68. Bradley, R.S., P. Cowin, & A.M. Brown . 1993. Expression of Wnt-1 in PC12 cells results in modulation of plakoglobin and E-cadherin and increased cellular adhesion. J. Cell Biol. 123: 1857-1865.
69. Poulsen, M., S.V. Porceddu, P.A. Kingsley, et al. 2007. Locally advanced tonsillar squamous cell carcinoma: treatment approach revisited. Laryngoscope 117: 45-50.
70. Lefebvre, J.L., D. Chevalier, B. Luboinski, et al. 1996. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. Natl. Cancer Inst. 88: 890-899.
71. Tsou, Y.A., M.H. Lin, C.H. Hua, et al. 2007. Survival outcome by early chemoradiation therapy salvage or early surgical salvage for the treatment of hypopharyngeal cancer. Otolaryngol. Head Neck Surg. 137: 711-716.
72. Weinstein, G.S., B.W. O'Malley, Jr., S.C. Desai, & H. Quon . 2009. Transoral robotic surgery: does the ends justify the means? Curr. Opin. Otolaryngol. Head and Neck Surg. 17: 126-131.
73. Jalisi, S., S. Bearelly, A. Abdillahi, & M.T. Truong . 2013. Outcomes in head and neck oncologic surgery at academic medical centers in the United States. Laryngoscope 123: 689-698.